• AAPL 183.875
  • TSLA 181.1141
  • AMZN 186.96
  • MSFT 405.935
  • INTC 30.94
  • EURUSD 1.0769
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. ST /
  3. CAMX.ST

Camurus AB (CAMX ST) stock market data APIs

kr494.5 0.1(0%) as of May 2, 2024

Camurus AB Financial Data Overview

494.29
494.5
-
499.36
485.75
246-599.5
28 927 M
66.8442
57 624 K
1 717 M
-0.27
0.844
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'CAMX',
Type: 'Common Stock',
Name: 'Camurus AB',
Exchange: 'ST',
CurrencyCode: 'SEK',
CurrencyName: 'Swedish krone',
CurrencySymbol: 'kr',
CountryName: 'Sweden',
CountryISO: 'SE',
OpenFigi: NULL,
ISIN: 'SE0007692850',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Camurus AB Fundamental Data is available in our Financial Data APIs

  • Net Revenue 1 717 M
  • EBITDA 536 M
  • Earnings Per Share 7.51
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Camurus AB Earnings via APIs

  • Latest Release 2024-03-21
  • EPS/Forecast 0.91

Get Camurus AB End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Camurus AB latest news via APIs

Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly

Favorable safety profile and effective biochemical control in 52-week trial Significant improvement of acromegaly symptoms vs. standard of care at baseline Improved patient reported treatment satisf...

Braeburn receives new Complete Response Letter for Brixadi in the US

LUND, Sweden, Dec. 15, 2021 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administ...
  • BRAEBURN
  • CAMURUS AB
  • COMPLETE RESPONSE LETTER
  • FREDRIK TIBERG
  • NEW DRUG APPLICATION
Do you have any questions?
support@eodhistoricaldata.com